Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
29.14
-0.26 (-0.88%)
Nov 12, 2026, 4:00 PM EST - Market closed
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
258
Market Cap
5.07B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 7.87M | -14.63M | -65.02% |
| Dec 31, 2019 | 22.50M | 12.77M | 131.14% |
| Dec 31, 2018 | 9.73M | 1.37M | 16.44% |
| Dec 31, 2017 | 8.36M | 2.01M | 31.55% |
| Dec 31, 2016 | 6.36M | 3.37M | 112.83% |
| Dec 31, 2015 | 2.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.16B |
| Mirum Pharmaceuticals | 670.78M |
| Travere Therapeutics | 651.03M |
| Ligand Pharmaceuticals | 253.83M |
| Dianthus Therapeutics | 2.72M |
| Scholar Rock Holding | 570.00K |
COGT News
- 1 day ago - Cogent Biosciences falls -6.8% - TheFly
- 2 days ago - Cogent Biosciences Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 3 days ago - Cogent Biosciences price target raised to $56 from $55 at H.C. Wainwright - TheFly
- 7 days ago - Cogent Biosciences reports Q3 net loss ($111.4M) vs. ($80.9M) last year - TheFly
- 7 days ago - Cogent Biosciences Earnings release: Q3 2026 - Filings
- 7 days ago - Cogent Biosciences Quarterly report: Q3 2026 - Filings
- 16 days ago - Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 1 month ago - Cogent Biosciences reports FDA acceptance of bezuclastinib new drug application - TheFly